Previous 10 | Next 10 |
LA JOLLA, Calif. , March 12, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the...
LA JOLLA, Calif. , Feb. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it initiated dosing of the second cohort of its P...
Gainers: Trillium Therapeutics (NASDAQ: TRIL ) +106% . More news on: Trillium Therapeutics Inc., Applied Genetic Technologies Corporation, Genetic Technologies Limited, Stocks on the move, Read more ...
LA JOLLA, Calif. , Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration ("FDA") has lifted...
LA JOLLA, Calif. , Nov. 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Office...
Regulus Therapeutics (NASDAQ: RGLS ): Q3 GAAP EPS of -$0.26 in-line. More news on: Regulus Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LA JOLLA, Calif. , Nov. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the third...
LA JOLLA, Calif. , Oct. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS) , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today announced that it presented preclinical data that identifies ...
LA JOLLA, Calif. , Sept. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has published an ar...
Durect (NASDAQ: DRRX ) initiated with Overweight rating and $5 (201% upside) price target at Cantor Fitzgerald. More news on: DURECT Corporation, Ekso Bionics Holdings, Inc., Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...